Enterprise Value
3.839M
Cash
69.09M
Avg Qtr Burn
-10.91M
Short % of Float
4.72%
Insider Ownership
1.43%
Institutional Own.
29.13%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Foselutoclax (UBX1325) (Bcl-xL inhibitor) Details Diabetic macular edema | Phase 2b Initiation | |
Foselutoclax (UBX1325) (Bcl-xL inhibitor) Details Diabetic retinopathy , Diabetic macular edema, Age-related macular degeneration | Phase 2a Data readout |